Logo image of NBIX

NEUROCRINE BIOSCIENCES INC (NBIX) Stock Fundamental Analysis

NASDAQ:NBIX - Nasdaq - US64125C1099 - Common Stock - Currency: USD

116.87  -3.56 (-2.96%)

After market: 121.03 +4.16 (+3.56%)

Fundamental Rating

7

Taking everything into account, NBIX scores 7 out of 10 in our fundamental rating. NBIX was compared to 562 industry peers in the Biotechnology industry. NBIX gets an excellent profitability rating and is at the same time showing great financial health properties. NBIX is not priced too expensively while it is growing strongly. Keep and eye on this one! This makes NBIX very considerable for growth and quality investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

In the past year NBIX was profitable.
NBIX had a positive operating cash flow in the past year.
Each year in the past 5 years NBIX has been profitable.
NBIX had a positive operating cash flow in each of the past 5 years.
NBIX Yearly Net Income VS EBIT VS OCF VS FCFNBIX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

1.2 Ratios

With an excellent Return On Assets value of 9.18%, NBIX belongs to the best of the industry, outperforming 94.84% of the companies in the same industry.
The Return On Equity of NBIX (13.18%) is better than 94.84% of its industry peers.
With an excellent Return On Invested Capital value of 13.20%, NBIX belongs to the best of the industry, outperforming 96.44% of the companies in the same industry.
NBIX had an Average Return On Invested Capital over the past 3 years of 11.40%. This is below the industry average of 14.31%.
The last Return On Invested Capital (13.20%) for NBIX is above the 3 year average (11.40%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 9.18%
ROE 13.18%
ROIC 13.2%
ROA(3y)7.79%
ROA(5y)10.24%
ROE(3y)11.14%
ROE(5y)15.22%
ROIC(3y)11.4%
ROIC(5y)11.57%
NBIX Yearly ROA, ROE, ROICNBIX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40

1.3 Margins

NBIX's Profit Margin of 14.49% is amongst the best of the industry. NBIX outperforms 95.02% of its industry peers.
NBIX's Profit Margin has improved in the last couple of years.
With an excellent Operating Margin value of 24.75%, NBIX belongs to the best of the industry, outperforming 96.44% of the companies in the same industry.
NBIX's Operating Margin has declined in the last couple of years.
NBIX has a Gross Margin of 98.56%. This is amongst the best in the industry. NBIX outperforms 97.51% of its industry peers.
In the last couple of years the Gross Margin of NBIX has remained more or less at the same level.
Industry RankSector Rank
OM 24.75%
PM (TTM) 14.49%
GM 98.56%
OM growth 3Y10.53%
OM growth 5Y-2.95%
PM growth 3Y22.39%
PM growth 5Y25.28%
GM growth 3Y-0.06%
GM growth 5Y-0.1%
NBIX Yearly Profit, Operating, Gross MarginsNBIX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

7

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), NBIX is creating some value.
The number of shares outstanding for NBIX has been increased compared to 1 year ago.
Compared to 5 years ago, NBIX has more shares outstanding
NBIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NBIX Yearly Shares OutstandingNBIX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
NBIX Yearly Total Debt VS Total AssetsNBIX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

An Altman-Z score of 7.70 indicates that NBIX is not in any danger for bankruptcy at the moment.
The Altman-Z score of NBIX (7.70) is better than 85.41% of its industry peers.
There is no outstanding debt for NBIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 7.7
ROIC/WACC1.31
WACC10.07%
NBIX Yearly LT Debt VS Equity VS FCFNBIX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B 2B 2.5B

2.3 Liquidity

A Current Ratio of 3.40 indicates that NBIX has no problem at all paying its short term obligations.
NBIX has a Current ratio of 3.40. This is in the lower half of the industry: NBIX underperforms 60.50% of its industry peers.
NBIX has a Quick Ratio of 3.28. This indicates that NBIX is financially healthy and has no problem in meeting its short term obligations.
NBIX has a Quick ratio (3.28) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.4
Quick Ratio 3.28
NBIX Yearly Current Assets VS Current LiabilitesNBIX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

8

3. Growth

3.1 Past

The earnings per share for NBIX have decreased strongly by -18.73% in the last year.
NBIX shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 58.39% yearly.
Looking at the last year, NBIX shows a very strong growth in Revenue. The Revenue has grown by 24.81%.
The Revenue has been growing by 24.48% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-18.73%
EPS 3Y35.58%
EPS 5Y58.39%
EPS Q2Q%-80.95%
Revenue 1Y (TTM)24.81%
Revenue growth 3Y27.61%
Revenue growth 5Y24.48%
Sales Q2Q%11.12%

3.2 Future

NBIX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 38.15% yearly.
NBIX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.63% yearly.
EPS Next Y27.36%
EPS Next 2Y40.05%
EPS Next 3Y40.71%
EPS Next 5Y38.15%
Revenue Next Year13.68%
Revenue Next 2Y14.45%
Revenue Next 3Y14.31%
Revenue Next 5Y12.63%

3.3 Evolution

The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
NBIX Yearly Revenue VS EstimatesNBIX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B 5B
NBIX Yearly EPS VS EstimatesNBIX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 10 15 20

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 39.62, the valuation of NBIX can be described as expensive.
Compared to the rest of the industry, the Price/Earnings ratio of NBIX indicates a rather cheap valuation: NBIX is cheaper than 93.06% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of NBIX to the average of the S&P500 Index (24.95), we can say NBIX is valued expensively.
NBIX is valuated rather expensively with a Price/Forward Earnings ratio of 18.11.
Based on the Price/Forward Earnings ratio, NBIX is valued cheaper than 92.53% of the companies in the same industry.
NBIX's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 20.99.
Industry RankSector Rank
PE 39.62
Fwd PE 18.11
NBIX Price Earnings VS Forward Price EarningsNBIX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

NBIX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. NBIX is cheaper than 95.20% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of NBIX indicates a rather cheap valuation: NBIX is cheaper than 95.20% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 20.75
EV/EBITDA 14.43
NBIX Per share dataNBIX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20 25

4.3 Compensation for Growth

NBIX's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
NBIX has an outstanding profitability rating, which may justify a higher PE ratio.
NBIX's earnings are expected to grow with 40.71% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.45
PEG (5Y)0.68
EPS Next 2Y40.05%
EPS Next 3Y40.71%

More info and screens

0

5. Dividend

5.1 Amount

NBIX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEUROCRINE BIOSCIENCES INC

NASDAQ:NBIX (5/13/2025, 8:00:01 PM)

After market: 121.03 +4.16 (+3.56%)

116.87

-3.56 (-2.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-05 2025-05-05/amc
Earnings (Next)07-30 2025-07-30/bmo
Inst Owners96.99%
Inst Owner Change-1.45%
Ins Owners1%
Ins Owner Change1.6%
Market Cap11.56B
Analysts83.13
Price Target158.86 (35.93%)
Short Float %4.63%
Short Ratio2.75
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-27.27%
Min EPS beat(2)-37.18%
Max EPS beat(2)-17.35%
EPS beat(4)0
Avg EPS beat(4)-38.78%
Min EPS beat(4)-59.17%
Max EPS beat(4)-17.35%
EPS beat(8)2
Avg EPS beat(8)-103.25%
EPS beat(12)2
Avg EPS beat(12)-88.07%
EPS beat(16)3
Avg EPS beat(16)-76.08%
Revenue beat(2)1
Avg Revenue beat(2)-0.31%
Min Revenue beat(2)-2.16%
Max Revenue beat(2)1.54%
Revenue beat(4)2
Avg Revenue beat(4)1.01%
Min Revenue beat(4)-2.16%
Max Revenue beat(4)5.99%
Revenue beat(8)4
Avg Revenue beat(8)0.67%
Revenue beat(12)7
Avg Revenue beat(12)1.15%
Revenue beat(16)8
Avg Revenue beat(16)0.23%
PT rev (1m)-4.56%
PT rev (3m)-7.01%
EPS NQ rev (1m)-25.96%
EPS NQ rev (3m)-57.35%
EPS NY rev (1m)-6.04%
EPS NY rev (3m)-34.41%
Revenue NQ rev (1m)-4.66%
Revenue NQ rev (3m)-10.02%
Revenue NY rev (1m)0.22%
Revenue NY rev (3m)-3.98%
Valuation
Industry RankSector Rank
PE 39.62
Fwd PE 18.11
P/S 4.91
P/FCF 20.75
P/OCF 19.42
P/B 4.47
P/tB 4.53
EV/EBITDA 14.43
EPS(TTM)2.95
EY2.52%
EPS(NY)6.45
Fwd EY5.52%
FCF(TTM)5.63
FCFY4.82%
OCF(TTM)6.02
OCFY5.15%
SpS23.81
BVpS26.17
TBVpS25.81
PEG (NY)1.45
PEG (5Y)0.68
Profitability
Industry RankSector Rank
ROA 9.18%
ROE 13.18%
ROCE 18.16%
ROIC 13.2%
ROICexc 32.81%
ROICexgc 33.77%
OM 24.75%
PM (TTM) 14.49%
GM 98.56%
FCFM 23.66%
ROA(3y)7.79%
ROA(5y)10.24%
ROE(3y)11.14%
ROE(5y)15.22%
ROIC(3y)11.4%
ROIC(5y)11.57%
ROICexc(3y)30.35%
ROICexc(5y)27.29%
ROICexgc(3y)31.58%
ROICexgc(5y)28.03%
ROCE(3y)15.68%
ROCE(5y)15.92%
ROICexcg growth 3Y35.59%
ROICexcg growth 5Y-0.37%
ROICexc growth 3Y34.3%
ROICexc growth 5Y-0.94%
OM growth 3Y10.53%
OM growth 5Y-2.95%
PM growth 3Y22.39%
PM growth 5Y25.28%
GM growth 3Y-0.06%
GM growth 5Y-0.1%
F-Score9
Asset Turnover0.63
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 140.96%
Cap/Sales 1.62%
Interest Coverage 364.38
Cash Conversion 97.59%
Profit Quality 163.26%
Current Ratio 3.4
Quick Ratio 3.28
Altman-Z 7.7
F-Score9
WACC10.07%
ROIC/WACC1.31
Cap/Depr(3y)126.53%
Cap/Depr(5y)144.2%
Cap/Sales(3y)1.41%
Cap/Sales(5y)1.47%
Profit Quality(3y)172.36%
Profit Quality(5y)166.13%
High Growth Momentum
Growth
EPS 1Y (TTM)-18.73%
EPS 3Y35.58%
EPS 5Y58.39%
EPS Q2Q%-80.95%
EPS Next Y27.36%
EPS Next 2Y40.05%
EPS Next 3Y40.71%
EPS Next 5Y38.15%
Revenue 1Y (TTM)24.81%
Revenue growth 3Y27.61%
Revenue growth 5Y24.48%
Sales Q2Q%11.12%
Revenue Next Year13.68%
Revenue Next 2Y14.45%
Revenue Next 3Y14.31%
Revenue Next 5Y12.63%
EBIT growth 1Y47.67%
EBIT growth 3Y41.04%
EBIT growth 5Y20.8%
EBIT Next Year-5.15%
EBIT Next 3Y24.31%
EBIT Next 5Y16.45%
FCF growth 1Y54.09%
FCF growth 3Y33.71%
FCF growth 5Y32.31%
OCF growth 1Y52.71%
OCF growth 3Y32.41%
OCF growth 5Y31.38%